Recent progress in the development of Toll-like receptor (TLR) antagonists

References

• Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16:343–353.
   PubMed Web of Science ®Google Scholar
• Loo Y-M, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34:680–692.
   PubMed Web of Science ®Google Scholar
• Osorio F, Reis E Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity. 2011;34:651–664.
   PubMed Web of Science ®Google Scholar
• Elinav E, Strowig T, Henao-Mejia J, et al. Regulation of the antimicrobial response by NLR proteins. Immunity. 2011;34:665–679.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–384.
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr., A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397.
   PubMed Web of Science ®Google Scholar
• Beutler BA. TLRs and innate immunity. Blood. 2009;113:1399–1407.
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449:819–826.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.
   PubMed Web of Science ®Google Scholar
• Hoffmann JA. The immune response of Drosophila. Nature. 2003;426:33–38.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511.
   PubMed Web of Science ®Google Scholar
• Lee BL, Moon JE, Shu JH, et al. UNC93B1 mediates differential trafficking of endosomal TLRs. Elife. 2013;2:e00291.
   PubMed Web of Science ®Google Scholar
• Huh J-W, Shibata T, Hwang M, et al. UNC93B1 is essential for the plasma membrane localization and signaling of Toll-like receptor 5. Proc Natl Acad Sci U S A. 2014;111:7072–7077.
   PubMed Web of Science ®Google Scholar
• Pohar J, Pirher N, Bencina M, et al. The role of UNC93B1 protein in surface localization of TLR3 receptor and in cell priming to nucleic acid agonists. J Biol Chem. 2013;288:442–454.
   PubMed Web of Science ®Google Scholar
• Kang JY, Nan X, Jin MS, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity. 2009;31:873–884.
   PubMed Web of Science ®Google Scholar
• Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007;130:1071–1082.
   PubMed Web of Science ®Google Scholar
• Park BS, Lee J-O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med. 2013;45:e66.
   PubMed Web of Science ®Google Scholar
• Yoon S-I, Kurnasov O, Natarajan V, et al. Structural basis of TLR5-flagellin recognition and signaling. Science. 2012;335:859–864.
   PubMed Web of Science ®Google Scholar
• Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science. 2008;320:379–381.
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526–1529.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–745.
   PubMed Web of Science ®Google Scholar
• Lee SM, Kok K-H, Jaume M, et al. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A. 2014;111:3793–3798.
   PubMed Web of Science ®Google Scholar
• Nagashima H, Iwatani S, Cruz M, et al. Toll-like receptor 10 in helicobacter pylori infection. J Infect Dis. 2015;212:1666–1676.
   PubMed Web of Science ®Google Scholar
• Regan T, Nally K, Carmody R, et al. Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. J Immunol. 2013;191:6084–6092.
   PubMed Web of Science ®Google Scholar
• Tanji H, Ohto U, Shibata T, et al. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science. 2013;339:1426–1429.
   PubMed Web of Science ®Google Scholar
• Latz E, Verma A, Visintin A, et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol. 2007;8:772–779.
   PubMed Web of Science ®Google Scholar
• Wu Y-W, Tang W, Zuo J-P. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015;36:1395–1407.
   PubMed Web of Science ®Google Scholar
• Jimenez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE. The critical role of toll-like receptors - From microbial recognition to autoimmunity: A comprehensive review. Autoimmun Rev. 2016;15:1–8.
   PubMed Web of Science ®Google Scholar
• Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9:293–307.
   PubMed Web of Science ®Google Scholar
• Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure. 2011;19:447–459.
   PubMed Web of Science ®Google Scholar
• Basith S, Manavalan B, Lee G, et al. Toll-like receptor modulators: a patent review (2006–2010). Expert Opin Ther Pat. 2011;21:927–944.
   PubMed Web of Science ®Google Scholar
• Hussein WM, Liu T-Y, Skwarczynski M, et al. Toll-like receptor agonists: a patent review (2011–2013). Expert Opin Ther Pat. 2014;24:453–470.
   PubMed Web of Science ®Google Scholar
• Singh VK, Pollard HB. Patents for Toll-like receptor ligands as radiation countermeasures for acute radiation syndrome. Expert Opin Ther Pat. 2015;25:1085–1092.
   PubMed Web of Science ®Google Scholar
• Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497:498–502.
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Tsuchimori N, Matsumoto T, et al. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol. 2011;79:34–41.
   PubMed Web of Science ®Google Scholar
• Cheng K, Wang X, Zhang S, et al. Discovery of small-molecule inhibitors of the TLR1/TLR2 complex. Angew Chem Int Ed Engl. 2012;51:12246–12249.
   PubMed Web of Science ®Google Scholar
• Mistry P, Laird MH, Schwarz RS, et al. Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain. Proc Natl Acad Sci U S A. 2015;112:5455–5460.
   PubMed Web of Science ®Google Scholar
• Koymans KJ, Feitsma LJ, Brondijk TH, et al. Structural basis for inhibition of TLR2 by staphylococcal superantigen-like protein 3 (SSL3). Proc Natl Acad Sci U S A. 2015;112:11018–11023.
   PubMed Web of Science ®Google Scholar
• Arslan F, Houtgraaf JH, Keogh B, et al. Treatment with OPN-305, a humanized anti-Toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012;5:279–287.
   PubMed Web of Science ®Google Scholar
• Liang Q, Wu Q, Jiang J, et al. Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem. 2011;286:26470–26479.
   PubMed Web of Science ®Google Scholar
• Oda M, Yamamoto H, Shibutani M, et al. Vizantin inhibits endotoxin-mediated immune responses via the TLR 4/MD-2 complex. J Immunol. 2014;193:4507–4514.
   PubMed Web of Science ®Google Scholar
• Selfridge BR, Wang X, Zhang Y, et al. Structure-activity relationships of (+)-Naltrexone-inspired Toll-like receptor 4 (TLR4) antagonists. J Med Chem. 2015;58:5038–5052.
   PubMed Web of Science ®Google Scholar
• De Paola M, Mariani A, Bigini P, et al. Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012;18:971–981.
   PubMed Web of Science ®Google Scholar
• Cighetti R, Ciaramelli C, Sestito SE, et al. Modulation of CD14 and TLR4.MD-2 activities by a synthetic lipid A mimetic. Chembiochem. 2014;15:250–258.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Peng Y, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. 2016;173:856–869.
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Ukai I, Yamagata Y, et al. Leucine-rich repeat 2 of human Toll-like receptor 4 contains the binding site for inhibitory monoclonal antibodies. FEBS Lett. 2015;589:3893–3898.
   PubMed Web of Science ®Google Scholar
• Cheng K, Wang X, Yin H. Small-molecule inhibitors of the TLR3/dsRNA complex. J Am Chem Soc. 2011;133:3764–3767.
   PubMed Web of Science ®Google Scholar
• Takemura N, Kawasaki T, Kunisawa J, et al. Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome. Nat Commun. 2014;5:3492.
   PubMed Web of Science ®Google Scholar
• Luo J, Obmolova G, Malia TJ, et al. Lateral clustering of TLR3: dsRNAsignaling units revealed by TLR3ecd:3Fabs quaternary structure. J Mol Biol. 2012;421:112–124.
   PubMed Web of Science ®Google Scholar
• Yan L, Liang J, Yao C, et al. Pyrimidine Triazole Thioether derivatives as Toll-like receptor 5 (TLR5)/Flagellin complex inhibitors. ChemMedChem. 2015. published online Dec 4 2015. doi:10.1002/cmdc.201500471.
   Web of Science ®Google Scholar
• Ashman RF, Goeken JA, Latz E, et al. Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Int Immunol. 2011;23:203–214.
   PubMed Web of Science ®Google Scholar
• Lamphier M, Zheng W, Latz E, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014;85:429–440.
   PubMed Web of Science ®Google Scholar
• Franklin BS, Ishizaka ST, Lamphier M, et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci U S A. 2011;108:3689–3694.
   PubMed Web of Science ®Google Scholar
• David BT, Ratnayake A, Amarante MA, et al. A toll-like receptor 9 antagonist reduces pain hypersensitivity and the inflammatory response in spinal cord injury. Neurobiol Dis. 2013;54:194–205.
   PubMed Web of Science ®Google Scholar
• Hoque R, Farooq A, Malik A, et al. A novel small-molecule enantiomeric analogue of traditional (-)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. J Immunol. 2013;190:4297–4304.
   PubMed Web of Science ®Google Scholar
• Kandimalla ER, Bhagat L, Wang D, et al. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 2013;41:3947–3961.
   PubMed Web of Science ®Google Scholar
• Sarvestani ST, Stunden HJ, Behlke MA, et al. Sequence-dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors. Nucleic Acids Res. 2015;43:1177–1188.
   PubMed Web of Science ®Google Scholar
• Piao W, Shirey KA, Ru LW, et al. A decoy peptide that disrupts TIRAP recruitment to TLRs is protective in a murine model of influenza. Cell Rep. 2015;11:1941–1952.
   PubMed Web of Science ®Google Scholar
• Hughes AL, Piontkivska H. Functional diversification of the toll-like receptor gene family. Immunogenetics. 2008;60:249–256.
   PubMed Web of Science ®Google Scholar
• Roach JC, Glusman G, Rowen L, et al. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A. 2005;102:9577–9582.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin H, Zhao M, et al. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2014;47:136–147.
   PubMed Web of Science ®Google Scholar
• Opsona Therapeutics, Ltd. Humanised antibodies to toll-like receptor 2 and uses thereof. US8734794; 2014.
   Google Scholar
• Reilly M, Miller RM, Thomson MH, et al. Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody. Clin Pharmacol Ther. 2013;94:593–600.
   PubMed Web of Science ®Google Scholar
• Opsona Therapeutics, Ltd. Toll-like receptor 2 binding epitope and binding members thereto. WO2013144345; 2013.
   Google Scholar
• Umc Utrecht Holding BV. Use of staphylococcal superantigen- like 3 (ssl3) as an tlr2 inhibitor. WO2013034736; 2013.
   Google Scholar
• Yeda Research and Development Co., Ltd. Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation. US8986712; 2015.
   Google Scholar
• Yeda Research and Development Co., Ltd. Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases. US20130225478; 2013.
   Google Scholar
• Murgueitio MS, Henneke P, Glossmann H, et al. Prospective virtual screening in a sparse data scenario: design of small-molecule TLR2 antagonists. ChemMedChem. 2014;9:813–822.
   PubMed Web of Science ®Google Scholar
• The Regents of The University of Colorado, A Body Corporate. Antagonists of the toll-like receptor 1/2 complex. WO2014022287; 2014.
   Google Scholar
• Richer MJ, Lavallee DJ, Shanina I, et al. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One. 2009;4:e4127.
   PubMed Web of Science ®Google Scholar
• Guo Y, Audry M, Ciancanelli M, et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med. 2011;208:2083–2098.
   PubMed Web of Science ®Google Scholar
• Carton JM, Chen S, Cunningham M, et al. Toll like receptor 3 antagonists, methods and uses. US8153583; 2012.
   Google Scholar
• Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists. US20140212426; 2014.
   Google Scholar
• The Regents of The University of Colorado, A Body Corporate. Modulators of tlr3/dsrna complex and uses thereof. WO2012099785; 2012.
   Google Scholar
• The University of Tokyo. Pharmaceutical composition for preventing or treating radiation-induced gastrointestinal syndrome. WO2015016282; 2015.
   Google Scholar
• Cadila Pharmaceuticals. Poly TLR antagonist. US8333978; 2012.
   Google Scholar
• Sehgal IS, Agarwal R, Aggarwal AN, et al. A randomized trial of Mycobacterium w in severe sepsis. J Crit Care. 2015;30:85–89.
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh—of the Commonwealth System of Higher Education. TLR4 inhibitors for the treatment of human infectious and inflammatory disorders. US9072760; 2015.
   Google Scholar
• Lv L, Gu X, Tang J, et al. Antioxidant activity of stilbene glycoside from Polygonum multiflorum Thunb in vivo. Food Chemistry. 2007;104:1678–1681.
   Web of Science ®Google Scholar
• Hussain S, Slevin M, Ahmed N, et al. Stilbene glycosides are natural product inhibitors of FGF-2-induced angiogenesis. BMC Cell Biol. 2009;10:30.
   PubMed Web of Science ®Google Scholar
• Park W-H, Lee S-J, Moon H-I. Antimalarial activity of a new stilbene glycoside from Parthenocissus tricuspidata in mice. Antimicrob Agents Chemother. 2008;52:3451–3453.
   PubMed Web of Science ®Google Scholar
• Yunnan University of Traditional Chinese Medicine. Application of stibene glucoside in preparing toll like receptor 4 (TLR4) innate immune system inhibitor. CN104546874; 2015.
   Google Scholar
• Zhejiang University. Application of ginsenoside Rg1 in preparation of medicine for preventing antiendotoxin from acting on Toll-like receptor 4. CN103622982 2014.
   Google Scholar
• Wang X, Loram LC, Ramos K, et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci U S A. 2012;109:6325–6330.
   PubMed Web of Science ®Google Scholar
• The Regents of the University of Colorado, A Body Corporate. Toll-like receptor modulators and uses thereof. US8642614; 2014.
   Google Scholar
• Bevan DE, Martinko AJ, Loram LC, et al. Selection, preparation, and evaluation of small- molecule inhibitors of Toll-like receptor 4. ACS Med Chem Lett. 2010;1:194–198.
   PubMed Web of Science ®Google Scholar
• Allodynic Therapeutics, LLC. Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor. WO2014160077; 2014.
   Google Scholar
• Leventhal JS, Schroppel B. Toll-like receptors in transplantation: sensing and reacting to injury. Kidney Int. 2012;81:826–832.
   PubMed Web of Science ®Google Scholar
• Novimmune SA Anti-TLR4 antibodies and methods of use thereof. US8734790; 2014.
   Google Scholar
• Atif SM, Uematsu S, Akira S, et al. CD103-CD11b+ dendritic cells regulate the sensitivity of CD4 T-cell responses to bacterial flagellin. Mucosal Immunol. 2014;7:68–77.
   PubMed Web of Science ®Google Scholar
• Rutkowski MR, Stephen TL, Svoronos N, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell. 2015;27:27–40.
   PubMed Web of Science ®Google Scholar
• Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228–231.
   PubMed Web of Science ®Google Scholar
• Klimosch SN, Forsti A, Eckert J, et al. Functional TLR5 genetic variants affect human colorectal cancer survival. Cancer Res. 2013;73:7232–7242.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–650.
   PubMed Web of Science ®Google Scholar
• Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320:226–230.
   PubMed Web of Science ®Google Scholar
• Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 5 expression by antisense oligonucleotides. US8153777; 2012.
   Google Scholar
• Thompson AD, Dugan A, Gestwicki JE, et al. Fine-tuning multiprotein complexes using small molecules. ACS Chem Biol. 2012;7:1311–1320.
   PubMed Web of Science ®Google Scholar
• Mallinckrodt, Inc. (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof. WO2011009015; 2011.
   Google Scholar
• Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56:2088–2097.
   PubMed Web of Science ®Google Scholar
• Rahn KA, McLaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis. Brain Res. 2011;1381:243–253.
   PubMed Web of Science ®Google Scholar
• Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33:451–459.
   PubMed Web of Science ®Google Scholar
• Cancer Vaccine Institute. Treatment of cancer with naltrexone. WO2014181131; 2014.
   Google Scholar
• Dynavax Technologies Corp. Methods of treatment using TLR7 and/or TLR9 inhibitors. US8940310; 2015.
   Google Scholar
• Dynavax Technologies Corp. Human toll-like receptor inhibitors and methods of use thereof. US9228184; 2016.
   Google Scholar
• Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response. US20140193396; 2014.
   Google Scholar
• Beesu M, Caruso G, Salyer AC, et al. Identification of a human toll-like receptor (TLR) 8-specific agonist and a functional pan-TLR inhibitor in 2-aminoimidazoles. J Med Chem. 2016; doi:10.1021/acs.jmedchem.6b00023. published online Mar 22 2016
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–4804.
   PubMed Web of Science ®Google Scholar
• Sun S, Rao NL, Venable J, et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007;6:223–235.
   PubMedGoogle Scholar
• Borchers AT, Naguwa SM, Keen CL, et al. Immunopathogenesis of Sjogren’s syndrome. Clin Rev Allergy Immunol. 2003;25:89–104.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. Jama. 2014;312:249–258.
   PubMed Web of Science ®Google Scholar
• Sullenger BA Inhibition of endosomal toll-like receptor activation. US20120183564; 2012.
   Google Scholar
• Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway. WO2012118911; 2012.
   Google Scholar
• Toshchakov VY, Szmacinski H, Couture LA, et al. Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface. J Immunol. 2011;186:4819–4827.
   PubMed Web of Science ®Google Scholar
• Nanjing University of Chinese Medicine. Application of sparstolenin B as TLR2 (Toll-like receptor 2)/TLR4 (Toll-like receptor 4) antagonist in pharmacy. CN102218058; 2013.
   Google Scholar
• Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38:1685–1694.
   PubMed Web of Science ®Google Scholar
• Opal SM, Laterre P-F, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. Jama. 2013;309:1154–1162.
   PubMed Web of Science ®Google Scholar
• Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol. 2013;4:387.
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, Yu J-W, Datta P, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458:509–513.
   PubMed Web of Science ®Google Scholar
• Barber GN. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol. 2011;23:10–20.
   PubMed Web of Science ®Google Scholar
• Unterholzner L, Keating SE, Baran M, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11:997–1004.
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174:1259–1268.
   PubMed Web of Science ®Google Scholar
• Jarvis LM. The Year In New Drugs. Chem Eng News. 2016 February;1:12–17.
   Google Scholar